Developing game changing treatments and cell therapies for severe diseases
We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our drug candidates have the potential to improve outcomes in the treatment of neurological and ophthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
News
TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.
The trial outcomes demonstrated that: TikoMed is now moving forward with planning a phase IIb multi-centre efficacy trial of ILB® Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed
The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for
The Division of Clinical Neuroscience vid Oslo universitetssjukhus och det svenska biofarmabolaget TikoMed har officiellt undertecknat ett forskningssamarbetsavtal.
Oslo, 27 juni, 2024. The Division of Clinical Neuroscience vid Oslo universitetssjukhus och det svenska biofarmabolaget TikoMed har nyligen undertecknat ett forskningssamarbetsavtal. Parterna är överens om att samarbetet ska leda